News
September 11, 2025
Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target
TORONTO, Sept. 10, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different [...]
TORONTO, Sept. 10, 2025 – Quantum BioPharma is making waves in the investment community as Kingswood Capital Partners announced today the initiation of analyst coverage on the company, issuing a “BUY” rating and setting a price target of US$45 per share. This positive assessment signals strong confidence in Quantum BioPharma's future prospects and potential for growth within the biopharmaceutical sector.
The announcement, released this morning, highlights Kingswood Capital Partners’ belief in Quantum BioPharma's strategic direction and its commitment to developing groundbreaking treatments for a range of debilitating conditions. Quantum BioPharma, traded on the NASDAQ and CSE exchanges under the ticker QNTM, as well as on the Frankfurt Stock Exchange (FRA: 0K91) and Upstream (QNTM), is focused on building a robust portfolio of innovative assets and biotech solutions.
The company's research and development efforts are primarily concentrated on tackling challenging neurodegenerative and metabolic disorders. These complex conditions, which often have limited treatment options, represent a significant unmet medical need. Quantum BioPharma is also actively pursuing solutions for alcohol misuse disorders, another area where innovative therapies are urgently required.
Kingswood Capital Partners' bullish outlook is likely fueled by Quantum BioPharma's promising drug candidates, which are currently in various stages of development. While the specific details of these candidates were not disclosed, the announcement emphasizes the diverse pipeline of the company, suggesting a well-balanced approach to therapeutic innovation.
The "BUY" rating from Kingswood Capital Partners is expected to draw increased attention to Quantum BioPharma from both institutional and retail investors. The US$45 price target indicates a significant potential upside for the stock, reflecting Kingswood's assessment of the company's intrinsic value and growth trajectory. This positive coverage could lead to increased trading volume and heightened investor interest in the company's future announcements regarding clinical trials, regulatory milestones, and potential partnerships.
The news is undoubtedly a significant boost for Quantum BioPharma, validating its strategic vision and underscoring the potential of its research and development programs to address critical healthcare challenges. As Quantum BioPharma continues to advance its pipeline of innovative therapies, it is poised to become a key player in the fight against neurodegenerative, metabolic, and alcohol misuse disorders.
The announcement, released this morning, highlights Kingswood Capital Partners’ belief in Quantum BioPharma's strategic direction and its commitment to developing groundbreaking treatments for a range of debilitating conditions. Quantum BioPharma, traded on the NASDAQ and CSE exchanges under the ticker QNTM, as well as on the Frankfurt Stock Exchange (FRA: 0K91) and Upstream (QNTM), is focused on building a robust portfolio of innovative assets and biotech solutions.
The company's research and development efforts are primarily concentrated on tackling challenging neurodegenerative and metabolic disorders. These complex conditions, which often have limited treatment options, represent a significant unmet medical need. Quantum BioPharma is also actively pursuing solutions for alcohol misuse disorders, another area where innovative therapies are urgently required.
Kingswood Capital Partners' bullish outlook is likely fueled by Quantum BioPharma's promising drug candidates, which are currently in various stages of development. While the specific details of these candidates were not disclosed, the announcement emphasizes the diverse pipeline of the company, suggesting a well-balanced approach to therapeutic innovation.
The "BUY" rating from Kingswood Capital Partners is expected to draw increased attention to Quantum BioPharma from both institutional and retail investors. The US$45 price target indicates a significant potential upside for the stock, reflecting Kingswood's assessment of the company's intrinsic value and growth trajectory. This positive coverage could lead to increased trading volume and heightened investor interest in the company's future announcements regarding clinical trials, regulatory milestones, and potential partnerships.
The news is undoubtedly a significant boost for Quantum BioPharma, validating its strategic vision and underscoring the potential of its research and development programs to address critical healthcare challenges. As Quantum BioPharma continues to advance its pipeline of innovative therapies, it is poised to become a key player in the fight against neurodegenerative, metabolic, and alcohol misuse disorders.
Category:
Politics